诺和诺德(NVO.US)涨超2.5%,最高触及58.67美元,创7月末以来新高。
消息面上,诺和诺德表示,新型减肥药Cagrilintide在一项晚期临床试验中展现出良好结果。每周一次的Cagrilintide单药注射在68周后帮助患者平均减重11.8%,而安慰剂组仅为2.3%。此外,Cagrilintide的耐受性良好,最常见的副作用为胃肠道反应,且大多为轻度至中度。(格隆汇)

本文地址: http://www.jiaotongmi.com/article/5117.html
文章来源:admin
版权声明:除非特别标注,否则均为本站原创文章,转载时请以链接形式注明文章出处。
2025-11-11admin
2025-11-10admin
2025-11-09admin
2025-11-08admin
2025-11-07admin
2025-11-06admin
2025-11-05admin
2025-11-04admin
2025-11-03admin
2025-10-29admin
2025-09-08admin
2025-09-08admin
2025-09-13admin
2025-09-17admin
2025-09-08admin
2025-09-17admin
2025-09-09admin
2025-09-09admin
2025-09-13admin
2025-09-11admin
2025-09-08admin
2025-09-08admin
2025-09-08admin
2025-09-08admin
2025-09-09admin
2025-09-08admin
2025-09-08admin
2025-09-08admin
2025-09-08admin
2025-09-10admin
扫码二维码
获取最新动态
